-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
AbCellera Biologics (NASDAQ:ABCL) & MusclePharm (OTCMKTS:MSLP) Financial Contrast
AbCellera Biologics (NASDAQ:ABCL) & MusclePharm (OTCMKTS:MSLP) Financial Contrast
AbCellera Biologics (NASDAQ:ABCL – Get Rating) and MusclePharm (OTCMKTS:MSLP – Get Rating) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.
Valuation and Earnings
This table compares AbCellera Biologics and MusclePharm's revenue, earnings per share (EPS) and valuation.
Get AbCellera Biologics alerts:Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
AbCellera Biologics | $375.20 million | 10.36 | $153.46 million | $0.79 | 17.19 |
MusclePharm | $50.04 million | 0.07 | -$12.87 million | ($0.58) | -0.17 |
AbCellera Biologics has higher revenue and earnings than MusclePharm. MusclePharm is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings for AbCellera Biologics and MusclePharm, as provided by MarketBeat.Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
AbCellera Biologics | 0 | 0 | 6 | 0 | 3.00 |
MusclePharm | 0 | 0 | 0 | 0 | N/A |
AbCellera Biologics currently has a consensus price target of $28.40, indicating a potential upside of 109.13%. Given AbCellera Biologics' higher probable upside, analysts clearly believe AbCellera Biologics is more favorable than MusclePharm.
Institutional and Insider Ownership
44.4% of AbCellera Biologics shares are owned by institutional investors. Comparatively, 15.5% of MusclePharm shares are owned by institutional investors. 30.3% of AbCellera Biologics shares are owned by insiders. Comparatively, 60.7% of MusclePharm shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares AbCellera Biologics and MusclePharm's net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
AbCellera Biologics | 41.17% | 21.62% | 16.54% |
MusclePharm | -38.51% | N/A | -169.56% |
Volatility and Risk
AbCellera Biologics has a beta of -0.54, meaning that its share price is 154% less volatile than the S&P 500. Comparatively, MusclePharm has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500.
Summary
AbCellera Biologics beats MusclePharm on 11 of the 13 factors compared between the two stocks.
About AbCellera Biologics
(Get Rating)
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
About MusclePharm
(Get Rating)
MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada.
Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
AbCellera Biologics (NASDAQ:ABCL – Get Rating) and MusclePharm (OTCMKTS:MSLP – Get Rating) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.
艾伯賽樂生物(納斯達克:ABCL-GET Rating)和穆斯克爾帕姆(OTCMKTS:MSLP-GET Rating)都是醫藥公司,但哪隻股票更好?我們將根據這兩家公司的盈利能力、機構所有權、股息、風險、收益、分析師推薦和估值等方面的實力進行比較。
Valuation and Earnings
估值和收益
This table compares AbCellera Biologics and MusclePharm's revenue, earnings per share (EPS) and valuation.
該表格比較了AbCellera Biologics和MusclePharm的收入、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
AbCellera Biologics | $375.20 million | 10.36 | $153.46 million | $0.79 | 17.19 |
MusclePharm | $50.04 million | 0.07 | -$12.87 million | ($0.58) | -0.17 |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
AbCellera生物製品公司 | 3.752億美元 | 10.36 | 1.5346億美元 | $0.79 | 17.19 |
穆斯克爾帕姆 | 5,004萬美元 | 0.07 | -1287萬美元 | ($0.58) | -0.17 |
AbCellera Biologics has higher revenue and earnings than MusclePharm. MusclePharm is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.
AbCellera Biologics的收入和收益比MusclePharm更高。MusclePharm的市盈率低於AbCellera Biologics,這表明它目前是兩隻股票中更負擔得起的一隻。
Analyst Ratings
分析師評級
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
AbCellera Biologics | 0 | 0 | 6 | 0 | 3.00 |
MusclePharm | 0 | 0 | 0 | 0 | N/A |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
AbCellera生物製品公司 | 0 | 0 | 6 | 0 | 3.00 |
穆斯克爾帕姆 | 0 | 0 | 0 | 0 | 不適用 |
AbCellera Biologics currently has a consensus price target of $28.40, indicating a potential upside of 109.13%. Given AbCellera Biologics' higher probable upside, analysts clearly believe AbCellera Biologics is more favorable than MusclePharm.
AbCellera Biologics目前的共識目標價為28.4美元,表明潛在上行空間為109.13%。考慮到AbCellera Biologics更有可能的上行空間,分析師們顯然認為AbCellera Biologics比MusclePharm更有利。
Institutional and Insider Ownership
機構和內部人持股
44.4% of AbCellera Biologics shares are owned by institutional investors. Comparatively, 15.5% of MusclePharm shares are owned by institutional investors. 30.3% of AbCellera Biologics shares are owned by insiders. Comparatively, 60.7% of MusclePharm shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
AbCellera Biologics 44.4%的股份由機構投資者持有。相比之下,機構投資者持有MusclePharm 15.5%的股份。AbCellera Biologics 30.3%的股份由內部人士持有。相比之下,MusclePharm 60.7%的股份由內部人士持有。強大的機構持股表明,捐贈基金、大型基金管理公司和對衝基金相信,一家公司有望實現長期增長。
Profitability
盈利能力
This table compares AbCellera Biologics and MusclePharm's net margins, return on equity and return on assets.
此表比較了AbCellera Biologics和MusclePharm的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
AbCellera Biologics | 41.17% | 21.62% | 16.54% |
MusclePharm | -38.51% | N/A | -169.56% |
淨利潤率 | 股本回報率 | 資產回報率 | |
AbCellera生物製品公司 | 41.17% | 21.62% | 16.54% |
穆斯克爾帕姆 | -38.51% | 不適用 | -169.56% |
Volatility and Risk
波動性和風險
AbCellera Biologics has a beta of -0.54, meaning that its share price is 154% less volatile than the S&P 500. Comparatively, MusclePharm has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500.
AbCellera Biologics的貝塔係數為-0.54,這意味着其股價的波動性比標準普爾500指數低154%。相比之下,MusclePharm的貝塔係數為0.17,這意味着其股價的波動性比標準普爾500指數低83%。
Summary
摘要
AbCellera Biologics beats MusclePharm on 11 of the 13 factors compared between the two stocks.
AbCellera Biologics在兩隻股票之間進行比較的13個因素中有11個擊敗了MusclePharm。
About AbCellera Biologics
關於AbCellera Biologics
(Get Rating)
(獲取評級)
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
AbCellera Biologics Inc.開發抗體發現平臺。它的全棧、人工智能支持的抗體發現平臺搜索和分析自然免疫系統的數據庫,以發現可以開發為藥物的抗體。截至2021年12月31日,該公司有156個已完成、正在進行或與36個合作伙伴簽訂合同的發現項目。AbCellera Biologics Inc.與禮來公司有研究合作和許可協議。該公司成立於2012年,總部位於加拿大温哥華。
About MusclePharm
關於MusclePharm
(Get Rating)
(獲取評級)
MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada.
公司在美國和國際上開發、製造、營銷和分銷運動營養品和營養補充劑。該公司提供一系列高性能粉末、膠囊、片劑、凝膠和隨時可用的零食。該公司的MusclePharm品牌產品組合包括戰鬥蛋白粉和戰鬥擠壓蛋白棒;以及支鏈氨基酸、肌酸、谷氨醯胺、肉鹼、共軛亞油酸、魚油、多種維生素和其他產品等基本補充劑。該公司還提供FitMisse品牌的運動營養產品,這些產品主要是為女性身體制定的,以支持女性在體重管理、瘦肌肉質量、身體成分以及一般健康和健康方面的需求;以及FitMisse Energy和FitMisse Energy品牌的功能能量飲料。它向各種運動員和健身愛好者銷售其產品。該公司成立於2006年,總部設在內華達州拉斯維加斯。
Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
接受AbCellera生物製品日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收AbCellera Biologics和相關公司的最新新聞和分析師評級的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧